See full prescribing information for further detail.įor Medicaid and NC Health Choice Billing 15 mg/kg every 3 weeks with paclitaxel and cisplatin or paclitaxel and topotecan.

Persistent, recurrent, or metastatic cervical cancer:

10 mg/kg every 2 weeks with interferon-alfa.

15 mg/kg every 3 weeks with carboplatin and paclitaxel.

5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy after progression on a first-line bevacizumab product-containing regimenįirst-line non-squamous non-small cell lung cancer:.

Recommended Dose: Metastatic colorectal cancer:

Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan.

Metastatic renal cell carcinoma in combination with interferon-alfa.

Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment.

(Mvasi is not indicated for adjuvant treatment of colon cancer).

Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.

Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.

Injection: 400 mg/16 mL (25 mg/mL) in a single-dose vial Strength/Package Size(s): Injection: 100 mg/4 mL (25 mg/mL) in a single-dose vial Effective with date of service July 22, 2019, the North Carolina Medicaid and NC Health Choice programs cover bevacizumab-awwb injection, for intravenous use (Mvasi™) for adult use in the Physician Administered Drug Program when billed with HCPCS code Q5107 - Injection, bevacizumab, (Mvasi™), 10 mg.

C53 icd 10